Scarica l'app Stockscreener
63.53
5.25%
-3.52
Dopo l'orario di chiusura:
63.43
-0.10
-0.16%
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
INBX Should I Buy - intellectia.ai
Discipline and Rules-Based Execution in INBX Response - Stock Traders Daily
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 5.7%What's Next? - MarketBeat
US Market Recap: Will Inhibrx Biosciences Inc stock recover after earnings2026 Risk Factors & Verified Momentum Watchlists - baoquankhu1.vn
Fundamentals Check: Will Inhibrx Biosciences Inc stock go up in YEAR2026 Opening Moves & Daily Volume Surge Signals - baoquankhu1.vn
Value Recap: Does Inhibrx Biosciences Inc have consistent dividend growthInsider Selling & Weekly Setup with ROI Potential - baoquankhu1.vn
Inhibrx Biosciences Inc. (INBX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Inhibrx Biosciences partners with Sarcoma Alliance to advance patient education resources - Traders Union
Retail Trends: Is Inhibrx Biosciences Inc stock undervalued right now2026 Earnings Impact & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Volume Recap: Is Inhibrx Biosciences Inc affected by consumer sentimentTrend Reversal & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Inhibrx Biosciences FY25 Review: Catalyst-Driven Hold Ahead Of Key 2026 Data (INBX) - Seeking Alpha
Ideas Watch: Is Inhibrx Biosciences Inc stock undervalued right nowEarnings Performance Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 6.6%Here's Why - marketbeat.com
Inhibrx Biosciences (INBX) Expected to Announce Earnings on Tuesday - MarketBeat
Behavioral Patterns of INBX and Institutional Flows - Stock Traders Daily
Inhibrx Biosciences Reports 2025 Financial Results - Intellectia AI
Inhibrx Reports Q4 Revenue of $0, Cash Balance at $124.2M - Intellectia AI
Inhibrx Biosciences Reports Q4 Earnings Miss - Intellectia AI
INBX SEC FilingsInhibrx Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Inhibrx Inc stock surges on Q4 2025 earnings and key 2026 pipeline milestones - ad-hoc-news.de
Inhibrx Biosciences, Inc. 2025 Annual Report – Clinical Pipeline, Regulatory Progress, and Company Overview - Minichart
Inhibrx Biosciences (NASDAQ:INBX) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Inhibrx Biosciences Q4 net loss narrows as expenses fall - TradingView
Inhibrx Biosciences 10-K: $1.3M revenue, EPS $(9.04) - TradingView
[10-K] Inhibrx Biosciences, Inc. Files Annual Report | INBX SEC FilingForm 10-K - Stock Titan
Inhibrx Biosciences (NASDAQ: INBX) details 2025 loss and 2026 trial plans - Stock Titan
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results - Nasdaq
Stock Analysis: Is Inhibrx Biosciences Inc a turnaround story2026 Key Lessons & High Accuracy Trade Alerts - baoquankhu1.vn
Boothbay Fund Management LLC Boosts Holdings in Inhibrx Biosciences, Inc. $INBX - marketbeat.com
Growth Value: What is Inhibrx Biosciences Incs P E ratio telling usQuarterly Trade Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Latest INBX NewsInhibrx Announces Participation in Upcoming... - Stock Titan
Slotnik Capital LLC Sells 142,770 Shares of Inhibrx Biosciences, Inc. $INBX - MarketBeat
Inhibrx Biosciences Inc expected to post a loss of $2.08 a shareEarnings Preview - TradingView
7,388 Shares in Inhibrx Biosciences, Inc. $INBX Acquired by Dynamic Technology Lab Private Ltd - Defense World
(INBX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Inhibrx Biosciences : ESMO Sarcoma and Rare Cancers Congress 2026 (INBRX-109 in Ewing sarcoma Data Update Oral Presentation) - marketscreener.com
Market Trends: Is Inhibrx Biosciences Inc stock undervalued right now2026 Action & Growth Oriented Trade Recommendations - baoquankhu1.vn
Inhibrx Biosciences (INBX) to Release Quarterly Earnings on Monday - MarketBeat
Will Inhibrx Biosciences Inc stock recover after earnings2025 Key Lessons & Technical Pattern Based Buy Signals - baoquankhu1.vn
Inhibrx Announces Participation in Upcoming Scientific Conference - PR Newswire
Ewing sarcoma study of ozekibart takes stage at rare cancer congress - Stock Titan
How (INBX) Movements Inform Risk Allocation Models - Stock Traders Daily
INBX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsight - The Malaysian Reserve
INBX Technical Analysis & ETF Price Forecast - Intellectia AI
INBX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Inhibrx Biosciences Highlights 2026 Pipeline and Strategy - The Globe and Mail
Market Leaders: Is Inhibrx Biosciences Inc stock undervalued right nowWeekly Loss Report & Reliable Price Action Trade Plans - baoquankhu1.vn
Chipmakers Recap: Is RNAC vulnerable to short sellersBond Market & Fast Moving Stock Trade Plans - baoquankhu1.vn
Trading Systems Reacting to (INBX) Volatility - Stock Traders Daily
Readystate Asset Management LP Acquires 143,324 Shares of Inhibrx Biosciences, Inc. $INBX - MarketBeat
Contrasting Immuneering (NASDAQ:IMRX) and Inhibrx Biosciences (NASDAQ:INBX) - Defense World
Inhibrx Biosciences, Inc. $INBX Shares Sold by Credit Industriel ET Commercial - MarketBeat
Will Inhibrx Biosciences Inc. be affected by tariffsJuly 2025 Intraday Action & Accurate Intraday Trade Tips - mfd.ru
Merger Talk: Is Inhibrx Biosciences Inc stock a hidden gem2025 Volume Leaders & Weekly Watchlist of Top Performers - baoquankhu1.vn
What is the long term forecast for Inhibrx Biosciences Inc. stockEarnings Overview Summary & Pattern Based Trade Signal System - mfd.ru
Inhibrx Biosciences and Immuneering Compared in Financial Analysis - National Today
Inhibrx Biosciences (NASDAQ:INBX) Shares Down 6.8%Here's What Happened - MarketBeat
Will Inhibrx Biosciences Inc. stock return to pre crisis levels2025 Trade Ideas & Verified Stock Trade Ideas - mfd.ru
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):